Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Phase 2

Terminated

• Conditions: Anaplastic Thyroid Cancer
• Interventions: Drug: paclitaxel; Drug: CA4P; Drug: carboplatin

• Registration Number: NCT00507429
• Lead Sponsor: Mateon Therapeutics

Brief Summary

The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).

Detailed Description

Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for ATC, and no randomized comparative trials have been known to be conducted in this disease. One potential strategy is to combine the anti-tumor activity of the vascular disrupting agent combretastatin with conventional cytotoxic agents. This study will compare the overall survival of ATC patients treated with the triplet combination of combretastatin, paclitaxel, and carboplatin compared with the doublet treatment of paclitaxel and carboplatin.

Study Timeline

• Study First Submitted: 2007-07-25
• Study First Submitted QC: 2007-07-25
• Study First Posted: 2007-07-26
• Study Start: 2007-08
• Primary Completion: 2011-10
• Study Completion: 2011-11
• Results First Submitted: 2013-08-16
• Status Verified: 2014-02
• Results First Submitted QC: 2014-05-12
• Last Update Submitted: 2014-05-12
• Results First Posted: 2014-06-09
• Last Update Posted: 2014-06-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Anaplastic thyroid carcinoma histologically or cytologically confirmed by a pathology review
• Refractory to or progressed during or after therapy, or relapsed within 6 months following initial combined modality therapy (usually including systemic chemotherapy and radiation) for regionally advanced disease
• Systemic therapy is limited to one chemotherapy regimen that is clearly administered contiguously, (i.e., in an uninterrupted primary therapeutic approach)
• Prior radiation: 3 weeks must have elapsed since radiation and disease must be present beyond radiation ports
• Minimum of 3 weeks must have elapsed from the time of last chemotherapy prior to the first dose of study drug
• Patients with bulky thyroid/neck masses and/or suspicion of airway obstruction must undergo screening (indirect and direct laryngoscopy) to ensure patency of the trachea/airway prior to study enrollment and treatment
• ECOG Performance Score less than or equal to 2
• Adequate bone marrow reserve as evidenced by absolute neutrophil count (ANC) greater than 1,500/microL, platelet count greater than 75,000/microL.
• Adequate renal function as evidenced by serum creatinine less than or equal to 2.0 mg/dL (less than 177 micromol/L)
• Adequate hepatic function as evidenced by serum total bilirubin less than 2X greater than the upper limit of normal (ULN) (less than3X ULN in patients with liver metastases), AST (aspartate aminotransferase)/ALT (alanine aminotransferase) less than or equal to 3X the ULN for the local reference lab (less than or equal to 5X the ULN for patients with liver metastases)
• No clinically important sequelae from any prior surgery or radiotherapy.

Read More

Exclusion Criteria

• Tumors confined to the thyroid.
• Clinically evident brain metastasis, including symptomatic involvement, evidence of cerebral edema by CT or MRI, radiographic evidence of progression of brain metastasis since definitive therapy, or continued requirement for corticosteroids
• Patients who receive chemotherapy for metastatic disease after completion of a combined modality approach.
• History of malignancies other than ATC except curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current PSA of less than 4.0 mg/dL or microg/L
• Known hypersensitivity to CA4P, paclitaxel or carboplatin, or any of their components
• Receiving concurrent investigational therapy or who have received investigational therapy for any indication within 28 days of the first scheduled day of dosing
• Greater than Grade 2 peripheral neuropathy
• History of prior cerebrovascular event, including transient ischemic attack
• Uncontrolled hypertension (blood pressure greater than 150/100 mm Hg despite medication)
• Symptomatic vascular disease (e.g. intermittent claudication)
• History of unstable angina pectoris pattern, myocardial infarction (including non-Q wave MI) within the past 6 months, or NYHA Class III and IV congestive heart failure
• History of torsade de pointes
• Bradycardia (less than 60 b/m), heart block (excluding 1st degree block, being PR interval prolongation only), and congenital long QT syndrome
• Any ventricular arrhythmias, or new ST segment elevation or depression or Q wave on ECG
• Ejection fractions less than normal (i.e. less than 45%)
• QTc prolongation greater than 450 ms
• Requirement of any drugs known to prolong the QTc interval, including anti-arrhythmic medications
• Potassium concentrations below 4.0 mEq/dL and magnesium concentrations below 1.8 mg/dL despite being on an electrolyte supplement
• Requirement of any drugs known to prolong the QTc interval
• History of solid organ transplant or bone marrow transplant

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 2: Carboplatin + Paclitaxel	paclitaxel	Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
Arm 2: Carboplatin + Paclitaxel	carboplatin	Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
Arm 1: CA4P + Carboplatin + paclitaxel	CA4P	Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2

Primary Outcome Measures

Name	Time	Method
Overall Survival	From randomization to date last known alive

Secondary Outcome Measures

Name	Time	Method
To Determine Progression Free Survival	from randomization through end of study visit
To Determine Percentage of 1 Year Survival	from randomization through end of study visit

Trial Locations

Locations (41)

Kidwai Memorial Hospital; 🇮🇳 Bangalore, Karnataka, India

Christian Medial College; 🇮🇳 Vellore, Tamil Nadu, India

INT Napoli Fondazione Pascale; 🇮🇹 Napoli, Italy

Azienda Ospedaliero - Universitaria Pisana; 🇮🇹 Pisa, Italy

Southampton Hospital Oncology Centre; 🇬🇧 Southampton, United Kingdom

Royal Marsden Hospital and Institute of Cancer Research; 🇬🇧 London, United Kingdom

Winship Cancer Institute, Emory University; 🇺🇸 Atlanta, Georgia, United States

Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins; 🇺🇸 Baltimore, Maryland, United States

University of Texas M.D. Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Ireland Cancer Center/Division od Hematology; 🇺🇸 Cleveland, Ohio, United States

City Clinical Oncology Dispensary; 🇷🇺 Saint Petersburg, Russian Federation

All India Institute of Medical Sciences; 🇮🇳 New Delhi, Delhi, India

Lo Studio E la Cura; 🇮🇹 Milano, Italy

Istituto Oncologico Veneto (IOV) - IRCCS; 🇮🇹 Padova, Italy

West Virginia University; 🇺🇸 Morgantown, West Virginia, United States

Institutul Oncologic; 🇷🇴 Cluj-Napoca, Romania

University Hospital, Cairo; 🇪🇬 Cairo, Egypt

Shirdi Sai Baba Cancer Hospital; 🇮🇳 Manipal, Karnataka, India

Zaklad Medyczny Nuklearnej i Endykrynologii; 🇵🇱 Gliwice, Poland

Clinical County Hospital Sibiu; 🇷🇴 Sibiu, Romania

Belarus National Medical University; 🇧🇾 Minsk, Belarus

Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy; 🇧🇬 Sofia, Bulgaria

Regional Clinical Oncology Dispensary; 🇺🇦 Lvov, Ukraine

Beatson Oncology Centre, Gartnavel General Hospital; 🇬🇧 Glasgow, Scotland, United Kingdom

Regional Oncology Dispensary with Inpatient Sector; 🇧🇬 Plodiv, Bulgaria

Specialized Hospital for Active Treatment of Oncology; 🇧🇬 Sofia, Bulgaria

Mediciti Hospital; 🇮🇳 Hyderabaad, Andhra Pradesh, India

Tata Memorial Centre; 🇮🇳 Mumbai, Maharashtra, India

Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology; 🇮🇱 Tel-Aviv, Israel

Centr of Medical Oncology; 🇷🇴 Iasi, Romania

Emergency Clinical County Hospital "Sf. loan cel Nou"; 🇷🇴 Suceava, Romania

Ukrainian Academy of Medical Science; 🇺🇦 Lomonosova 33/43, Kiev, Ukraine

Klinika Nowotworow Glowy i Szyji; 🇵🇱 Warszawa, Poland

SC Meditech SRL; 🇷🇴 Craiova, Romania

University of Colorado Cancer Center; 🇺🇸 Aurora, Colorado, United States

Yale University, School of Medicine; 🇺🇸 New Haven, Connecticut, United States

University of Minnesota Otolaryngology Department; 🇺🇸 Minneapolis, Minnesota, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States

Apollo Cancer Institute; 🇮🇳 New Delhi, Delhi, India

Ruby Hall Clinic; 🇮🇳 Pune, Maharashtra, India